Literature DB >> 12373296

Plasma exchange therapy for the treatment of Escherichia coli O-157 associated hemolytic uremic syndrome.

Tatsuya Nakatani1, Kenji Tsuchida, Rikio Yoshimura, Kazunobu Sugimura, Yoshiaki Takemoto.   

Abstract

Plasma exchange (PE) therapy was administered to three patients with Escherichia coli O-157 associated hemolytic uremic syndrome (HUS) in early phase. Following several PE treatments, all cases completely recovered without any apparent complications. The usefulness of PE therapy in removing microbial fragments and inflammatory cytokines was evaluated. The peptidoglycan (PG) level, interleukin-1 receptor antagonist (IL-1Ra) were higher in HUS patients starting PE therapy than in patients who had received several sessions of PE therapy. PE therapy was an effective early phase treatment for Escherichia coli O-157 associated HUS.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373296

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  Neonatal hemolytic uremic syndrome after mother-to-child transmission of Escherichia coli O157.

Authors:  Tim Ulinski; Cyril Lervat; Bruno Ranchin; Yves Gillet; Daniel Floret; Pierre Cochat
Journal:  Pediatr Nephrol       Date:  2005-07-12       Impact factor: 3.714

2.  Clinical characteristics of children with hemolytic uremic syndrome in Hangzhou, China.

Authors:  Shui-Ai Zhao; Bo-Tao Ning; Jian-Hua Mao
Journal:  World J Pediatr       Date:  2017-03-28       Impact factor: 2.764

3.  Acute neurological involvement in diarrhea-associated hemolytic uremic syndrome.

Authors:  Sylvie Nathanson; Thérésa Kwon; Monique Elmaleh; Marina Charbit; Emma Allain Launay; Jérôme Harambat; Muriel Brun; Bruno Ranchin; Flavio Bandin; Sylvie Cloarec; Guylhene Bourdat-Michel; Christine Piètrement; Gérard Champion; Tim Ulinski; Georges Deschênes
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

4.  Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed.

Authors:  Diana Karpman
Journal:  Nephrol Dial Transplant       Date:  2012-10       Impact factor: 5.992

Review 5.  Pediatric Atypical Hemolytic Uremic Syndrome Advances.

Authors:  Rupesh Raina; Nina Vijayvargiya; Amrit Khooblall; Manasa Melachuri; Shweta Deshpande; Divya Sharma; Kashin Mathur; Manav Arora; Sidharth Kumar Sethi; Sonia Sandhu
Journal:  Cells       Date:  2021-12-18       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.